Your browser doesn't support javascript.
loading
Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction.
Min, Kyung-Duk; Matsumoto, Yuki; Asakura, Masanori; Ishihara, Masaharu.
Afiliación
  • Min KD; Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Hyogo, Japan.
  • Matsumoto Y; Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Hyogo, Japan.
  • Asakura M; Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Hyogo, Japan.
  • Ishihara M; Department of Cardiovascular and Renal Medicine, Hyogo Medical University, 1-1 Mukogawa-cho, Nishinomiya, 663-8501, Hyogo, Japan.
ESC Heart Fail ; 2024 May 09.
Article en En | MEDLINE | ID: mdl-38725278
ABSTRACT
The development of new drugs and device therapies has led to remarkable advancements in heart failure (HF) treatment in the past couple of decades. However, it becomes increasingly evident that guideline-directed medical therapy cannot be one-size-fits-all across a wide range of ejection fractions (EFs) and various aetiologies. Therefore, classifications solely relying on EF and natriuretic peptide make optimization of treatment challenging, and there is a growing exploration of new indicators that enable efficient risk stratification of HF patients. Particularly when considering HF as a multi-organ interaction syndrome, the cardiorenal interaction plays a central role in its pathophysiology, and albuminuria has gained great prominence as its biomarker, independent from glomerular filtration rate. Albuminuria has been shown to exhibit a linear correlation with cardiovascular disease and HF prognosis in multiple epidemiological studies, ranging from normal (<30 mg/g) to high levels (>300 mg/g). However, on the other hand, it is only recently that the details of the pathological mechanisms that give rise to albuminuria have begun to be elucidated, including the efficient compaction/tightening of the glomerular basement membrane by podocytes and mesangial cells. Interestingly, renal disease, diabetes, and HF damage these components associated with albuminuria, and experimental models have demonstrated that recently developed HF drugs reduce albuminuria by ameliorating these pathological phenotypes. In this review, facing the rapid expansion of horizons in HF treatment, we aim to clarify the current understanding of the pathophysiology of albuminuria and explore the comprehensive understanding of albuminuria by examining the clinically established evidence to date, the pathophysiological mechanisms leading to its occurrence, and the outcomes of clinical studies utilizing various drug classes committed to specific pathological mechanisms to put albuminuria as a novel axis to depict the pathophysiology of HF.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ESC Heart Fail Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: ESC Heart Fail Año: 2024 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido